journal
MENU ▼
Read by QxMD icon Read
search

British Journal of Haematology

journal
https://read.qxmd.com/read/31515804/a-novel-haemato-oncology-frailty-hof-score-tool-predicts-survival-in-over-80s-with-multiple-myeloma
#1
LETTER
Richard Hinton, Shuli Levy, Richard Szydlo, Simona Deplano
No abstract text is available yet for this article.
September 13, 2019: British Journal of Haematology
https://read.qxmd.com/read/31515799/extracavitary-primary-effusion-lymphoma-in-a-post-transplantation-patient
#2
Magda Zanelli, Clara Bertuzzi, Maurizio Zizzo, Giovanni Martino, Elena Sabattini, Stefano Ascani
No abstract text is available yet for this article.
September 13, 2019: British Journal of Haematology
https://read.qxmd.com/read/31515797/establishment-of-brain-natriuretic-peptide-based-criteria-for-evaluating-cardiac-response-to-treatment-in-light-chain-al-amyloidosis
#3
Brian Lilleness, Gheorghe Doros, Frederick L Ruberg, Vaishali Sanchorawala
Severity of cardiac involvement remains the leading determinant of survival in light chain (AL) amyloidosis. Until recently, cardiac response after treatment relied on reduction of N-terminal pro-brain natriuretic peptide (NT-proBNP). In this study, 94 patients with AL amyloidosis (baseline BNP ≥150 pg/ml) had BNP measured at 6 months following treatment. Median overall survival was not reached for cardiac response (≥50 pg/ml and ≥ 30% decrease in BNP), 9·2 years for cardiac stability (<50 pg/ml and <30% change in BNP) and 2·8 years for cardiac progression (≥50 pg/ml or ≥30% increase in BNP) (log-rank P < 0·001)...
September 13, 2019: British Journal of Haematology
https://read.qxmd.com/read/31509241/antenatal-screening-for-haemoglobinopathies-current-status-barriers-and-ethics
#4
REVIEW
Subarna Chakravorty, Moira C Dick
Sickle cell disease (SCD) and thalassaemia are genetic disorders that are caused by errors in the genes for haemoglobin and are some of the most common significant genetic disorders in the world, resulting in significant morbidity and mortality. Great disparities exist in the outcome of these conditions between resource- rich and resource-poor nations. Antenatal screening for these disorders aims to provide couples with information about their reproductive risk and enable them to make informed reproductive choices; ultimately reducing the likelihood of children being born with these conditions...
September 11, 2019: British Journal of Haematology
https://read.qxmd.com/read/31509226/acute-myeloid-leukaemia-with-auer-rods-within-pseudo-ch%C3%A3-diak-higashi-granules
#5
Jun Yin, Songshan Zhu, Yu Luo, Zhongyuan Lin, Yanyun Chen
No abstract text is available yet for this article.
September 11, 2019: British Journal of Haematology
https://read.qxmd.com/read/31498884/how-i-manage-severe-von-willebrand-disease
#6
REVIEW
Frank W G Leebeek, Ferdows Atiq
Von Willebrand disease (VWD) is the most common inherited bleeding disorder. Most patients with mild and moderate VWD can be treated effectively with desmopressin. The management of severe VWD patients, mostly affected by type 2 and type 3 disease, can be challenging. In this article we review the current diagnosis and treatment of severe VWD patients. We will also discuss the management of severe VWD patients in specific situations, such as pregnancy, delivery, patients developing alloantibodies against von Willebrand factor and VWD patients with recurrent gastrointestinal bleeding...
September 9, 2019: British Journal of Haematology
https://read.qxmd.com/read/31498883/influence-of-donor-type-stem-cell-source-and-conditioning-on-outcomes-after-haploidentical-transplant-for-lymphoma-a-lwp-ebmt-study
#7
Ali Bazarbachi, Ariane Boumendil, Hervé Finel, Luca Castagna, Alida Dominietto, Didier Blaise, Jose L Diez-Martin, Johanna Tischer, Zafer Gülbas, Hélène L Wallet, Lucia L Corral, Mohamad Mohty, Yener Koc, Ibrahim Yakoub-Agha, Christoph Schmid, Jean El Cheikh, Mutlu Arat, Edouard Forcade, Peter Dreger, Vanderson Rocha, Gonzalo G García, Yves Chalandon, Christelle Ferra, Corentin Orvain, Stephen Robinson, Silvia Montoto, Anna Sureda
Haploidentical stem cell transplantation (haploSCT) is becoming a major transplant modality for lymphoma. To assess the effects of donor characteristics, stem cell source and conditioning on outcomes, we identified 474 adults with Hodgkin (HL; 240), peripheral T-cell (PTCL; 88), diffuse large B-cell (77), mantle cell (40) or follicular lymphoma (FL; 29), who received haploSCT with post-transplant cyclophosphamide. Median follow-up of alive patients was 32 months. On multivariate analysis, acute graft-versus-host disease (GVHD) grade 2-4 was lower with offspring donors or bone marrow cells, whereas extensive chronic GVHD was higher in partial response at haploSCT or when using sisters, haploidentical donors beyond first degree, or female donors in male patients...
September 9, 2019: British Journal of Haematology
https://read.qxmd.com/read/31487392/infectious-complications-after-post-transplantation-cyclophosphamide-and-anti-thymocyte-globulin-based-haploidentical-stem-cell-transplantation
#8
LETTER
Razan Mohty, Eolia Brissot, Giorgia Battipaglia, Annalisa Ruggeri, Rémy Dulery, Agnès Bonnin, Clémence Médiavilla, Simona Sestili, Ramdane Belhocine, Anne Vekhoff, Tounes Ledraa, Camelia Simona Lapusan, Rosa Adaeva, Françoise Isnard, Olivier Legrand, Mohamad Mohty, Florent Malard
No abstract text is available yet for this article.
September 5, 2019: British Journal of Haematology
https://read.qxmd.com/read/31487388/lactate-dehydrogenase-is-elevated-in-immune-thrombocytopenia-and-inversely-correlates-with-platelet-count
#9
LETTER
Hanny Al-Samkari, David J Kuter
No abstract text is available yet for this article.
September 5, 2019: British Journal of Haematology
https://read.qxmd.com/read/31483479/detection-by-a-simple-and-cheaper-methodology-of-ik6-and-ik10-isoforms-of-the-ikzf1-gene-is-highly-associated-with-a-poor-prognosis-in-b-lineage-paediatric-acute-lymphoblastic-leukaemia
#10
LETTER
Larissa P Bueno, Rosane de P Queiróz, Veridiana K Suazo, Elisabeth Perna, Silvia R Brandalise, José A Yunes, Luiz G Tone, Carlos A Scrideli
No abstract text is available yet for this article.
September 4, 2019: British Journal of Haematology
https://read.qxmd.com/read/31483478/value-of-detecting-bone-marrow-involvement-in-hodgkin-lymphoma-response-to-adams-and-kwee
#11
LETTER
Mette A Pedersen, Lars C Gormsen, Francesco d'Amore
No abstract text is available yet for this article.
September 4, 2019: British Journal of Haematology
https://read.qxmd.com/read/31483060/central-nervous-system-emergencies-in-haematological-malignancies
#12
REVIEW
Macarena I de la Fuente, Juan Pablo Alderuccio, Izidore S Lossos
Neurological emergencies are frequently catastrophic events in the course of haematological malignancies (HM) that, if not promptly recognized and treated, may lead to lethal outcomes or chronic sequelae. They may occur at any time during the disease course, but are more frequently observed following relapse. Practice guidelines are lacking in the management of most central nervous system (CNS) complications in HM. Herein we review the pathophysiology, presentation and treatment of elevated intracranial pressure, spinal cord compression, status epilepticus, neurovascular complications, CNS infection, leucostasis and hyperviscosity...
September 4, 2019: British Journal of Haematology
https://read.qxmd.com/read/31475356/international-external-quality-assessment-for-measurements-of-direct-oral-anticoagulants-results-and-recommendations
#13
Martine J Hollestelle, Piet Meijer
There is limited information regarding the performance of tests for direct oral anticoagulants (DOACs). To generate more knowledge, the accuracy of DOAC tests were evaluated using external quality assessment data from multiple years. This data demonstrated a good correlation for the tests with a small overall interlaboratory variability (10% for dabigatran, rivaroxaban and apixaban and 12% for edoxaban). The greatest differences between the various reagents were observed for rivaroxaban, especially for concentrations below 100 ng/ml...
September 2, 2019: British Journal of Haematology
https://read.qxmd.com/read/31475355/who-is-the-best-relative-optimizing-haploidentical-donor-transplantation-in-lymphoma
#14
EDITORIAL
Abraham S Kanate, Bipin N Savani
No abstract text is available yet for this article.
September 2, 2019: British Journal of Haematology
https://read.qxmd.com/read/31475353/concomitant-erdheim-chester-disease-and-chronic-myelomonocytic-leukaemia-genomic-insights-into-a-common-clonal-origin
#15
LETTER
Gaurav Goyal, Yuanhang Liu, Aishwarya Ravindran, Aref Al-Kali, Ronald S Go, Mrinal M Patnaik, Karen L Rech
No abstract text is available yet for this article.
September 2, 2019: British Journal of Haematology
https://read.qxmd.com/read/31468521/a-phase-ii-study-of-addition-of-pracinostat-to-a-hypomethylating-agent-in-patients-with-myelodysplastic-syndromes-who-have-not-responded-to-previous-hypomethylating-agent-therapy
#16
Fevzi F Yalniz, Jesus G Berdeja, Michael B Maris, Roger M Lyons, James A Reeves, James H Essell, Prapti Patel, Mikkael Sekeres, Amanda Hughes, Silvia Mappa, Guillermo Garcia-Manero
Hypomethylating agents (HMAs) are standard of care for higher-risk myelodysplastic syndromes (MDS). However, less than half of patients achieve objective responses and most eventually lose their response. Pracinostat is a pan-histone deacetylase inhibitor with demonstrated activity in advanced myeloid malignancies. This phase II study explored the benefit of adding pracinostat to HMAs in MDS patients who did not respond to single-agent HMA treatment. The goal was to estimate the clinical improvement rate [complete remission (CR), marrow CR, partial response (PR) and haematological improvement]...
August 29, 2019: British Journal of Haematology
https://read.qxmd.com/read/31468517/in-situ-bcl2-expression-is-an-independent-prognostic-factor-in-hiv-associated-dlbcl-a-lymphovir-cohort-study
#17
Laure Philippe, Remi Lancar, Camille Laurent, Michele Algarte-Genin, Catherine Chassagne-Clément, Bettina Fabiani, Marie Pierre Chenard, Thierry Lazure, Marie Parrens, Frederic Charlotte, Claire Delattre, Laure Gibault, Frederique Capron, Isabelle Goubin-Versini, Bruno Petitjean, François Boué, Nicolas Mounier, Regis Costello, Dominique Costagliola, Sophie Prevot, Caroline Besson
The prognostic value of cell of origin (COO) classification and BCL2 expression is not well established in diffuse large B-cell lymphoma (DLBCL) patients with human immunodeficiency virus (HIV) infection in the recent era. Phenotypic patterns were determined by immunohistochemistry (IHC) of pathological samples from patients with HIV-associated DLBCL prospectively enrolled in the French AIDS and Viral Hepatitis CO16 Lymphovir cohort between 2008 and 2015. Molecular subgroup classification into germinal centre B-cell (GCB) and non-GCB subtypes was determined using the Hans algorithm...
August 29, 2019: British Journal of Haematology
https://read.qxmd.com/read/31468508/ibrutinib-monotherapy-outside-of-clinical-trial-setting-in-waldenstr%C3%A3-m-macroglobulinaemia-practice-patterns-toxicities-and-outcomes
#18
Jithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, Morie A Gertz, Shaji Kumar, Michelle Manske, Anne J Novak, Rebecca King, Patricia Greipp, Ronald Go, David Inwards, Eli Muchtar, Thomas Habermann, Thomas E Witzig, Carrie A Thompson, David Dingli, Martha Q Lacy, Nelson Leung, Angela Dispenzieri, Wilson Gonsalves, Rahma Warsame, Robert A Kyle, Vincent Rajkumar, Sameer A Parikh, Prashant Kapoor
Ibrutinib-related data in Waldenström macroglobulinaemia (WM) remain sparse, particularly outside of trials. We report on 80 patients [previously treated, n = 67 (84%), treatment-naïve, n = 13 (16%)] with WM, evaluated consecutively at Mayo Clinic, who received ibrutinib off-study after its approval in 2015 for WM. Overall response rate (ORR) was 91%; major-response rate (MRR) was 78%. The median time to first response and best response was 2·9 [95% confidence interval (CI): 2-4] and 5·7 (95% CI: 4-12) months, respectively...
August 29, 2019: British Journal of Haematology
https://read.qxmd.com/read/31468506/a-journey-through-infectious-risk-associated-with-ruxolitinib
#19
REVIEW
Emanuela Sant'Antonio, Massimiliano Bonifacio, Massimo Breccia, Elisa Rumi
Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval led to a significant change in the current treatment algorithm. Despite its efficacy and beyond its well described haematological toxicity, a peculiar immunosuppressive effect emerged as our clinical experience grew, both within and outside of a clinical trial setting. Definite and negative interactions with multiple pathways of the immune system of patients have been reported so far, involving both adaptive and innate immune responses...
August 29, 2019: British Journal of Haematology
https://read.qxmd.com/read/31452197/will-daratumumab-be-the-next-game-changer-in-early-thymic-precursor-acute-lymphoblastic-leukaemia
#20
LETTER
Sumeet Mirgh, Rayaz Ahmed, Narendra Agrawal, Vishvdeep Khushoo, Ambar Garg, Shinto Francis, Narender Tejwani, Neha Singh, Dinesh Bhurani
No abstract text is available yet for this article.
August 26, 2019: British Journal of Haematology
journal
journal
20057
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"